Mounjaro Dosage: Research Literature vs Medical Advice
Tirzepatide Research
Dual GIP/GLP-1 Agonism
Last Updated: May 2026
Prescription-Only Medicine — Important Notice
Mounjaro (tirzepatide) is a Prescription Only Medicine in the UK and most jurisdictions. It requires a valid prescription from a licensed prescriber. Pure Grade Labs does not sell Mounjaro and cannot provide prescribing advice, dosing guidance, or medical recommendations of any kind. This article explains what the SURPASS clinical trial programme studied — it is not a dosing guide and should not be treated as one. If you need Mounjaro, speak to a licensed medical prescriber. Pure Grade Labs supplies research-grade tirzepatide strictly for laboratory research purposes only. Not for human consumption.
Searches for “Mounjaro dosage” have surged dramatically since tirzepatide’s UK approval in 2023, and we want to be direct about what this article can and cannot give you. If you are looking for instructions on how to self-administer Mounjaro, this is not that article — because dosing decisions for a Prescription Only Medicine belong to licensed prescribers, not to research chemical suppliers or information articles. What this article does provide is a detailed, research-focused explanation of what the SURPASS clinical trial programme investigated across tirzepatide dose levels of 5mg, 10mg, and 15mg once weekly — the pharmacological rationale for the dose escalation design, the published efficacy outcomes at each dose level, and how tirzepatide’s dual mechanism as a GIP receptor and GLP-1 receptor agonist distinguishes it from earlier compounds in the class. For researchers studying GIP and GLP-1 receptor pharmacology, Pure Grade Labs supplies research-grade tirzepatide 10mg for in vitro laboratory research only — not for human consumption. If you need Mounjaro as a patient, speak to a licensed prescriber.
Key Takeaways
- Mounjaro is a Prescription Only Medicine: Tirzepatide requires a valid prescription from a licensed prescriber who can assess contraindications, current medications, cardiovascular risk, and clinical appropriateness. No article, website, or research supplier can substitute for this clinical process.
- The SURPASS programme studied three therapeutic doses: Tirzepatide was evaluated at 5mg, 10mg, and 15mg once weekly across SURPASS-1 through SURPASS-5 trials. A 2.5mg once-weekly dose was used only as an initiation step for tolerability — it is not a therapeutic dose in the trial literature.
- SURPASS-2 head-to-head with semaglutide: At 15mg, tirzepatide achieved a mean HbA1c reduction of −2.46% vs. −2.07% for semaglutide 1mg over 40 weeks — the largest between-drug difference recorded in a head-to-head GLP-1 class trial to that date.
- SURMOUNT-1 obesity data: In participants without diabetes, 15mg tirzepatide produced a mean body weight reduction of 20.9% (~22.5 kg) over 72 weeks, with 63% of participants achieving ≥20% weight reduction — outcomes that established tirzepatide as the highest-efficacy incretin agonist studied in clinical trials.
- Dual mechanism sets it apart: Unlike semaglutide (GLP-1 receptor agonist only), tirzepatide activates both the GIP receptor and the GLP-1 receptor — a mechanism studied by researchers interested in the additive or synergistic metabolic effects of co-agonism. Research-grade tirzepatide 10mg is available from Pure Grade Labs for laboratory investigation.
- Next frontier in the class: Retatrutide extends dual agonism to triple agonism (GIP/GLP-1/glucagon receptors) — the subject of active Phase III investigation and a research tool of growing interest to metabolic pharmacologists.
Research-Grade Tirzepatide — UK Supply
Tirzepatide 10mg for laboratory research. 99%+ HPLC-verified purity. Batch COA included. Not for human consumption.
Prescription-only medicine in many jurisdictions. For research purposes only.
Why the Search Volume for “Mounjaro Dosage” Has Exploded
Tirzepatide — marketed as Mounjaro by Eli Lilly — received UK MHRA approval for type 2 diabetes management in November 2023, and subsequent approval for chronic weight management under the brand name Mounjaro in 2024. It is the first medicine in a new pharmacological class: dual agonists targeting both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor simultaneously. This dual mechanism — and the extraordinary efficacy outcomes published from the SURPASS and SURMOUNT trial programmes — drove a surge of public and clinical interest that has translated into very high search volumes for terms like “Mounjaro dosage,” “Mounjaro 5mg,” “Mounjaro 10mg,” “Mounjaro 15mg,” and “tirzepatide dosage.”
People searching these terms fall into recognisable groups: patients currently prescribed or considering Mounjaro who want to understand what doses exist; healthcare professionals looking for a rapid research overview; and researchers in metabolic pharmacology who want to understand the dose-response relationships studied in published clinical trials. This article addresses the third group most directly — and provides context to the second — but will not serve the first group with prescribing guidance, because that is not something this article or this company can legitimately provide.
The answer to “what Mounjaro dosage should I take?” is always: ask your prescriber. The answer to “what doses did the SURPASS clinical trials study, and what did the outcomes show?” is in the published literature — and that is what this article explains.
What Mounjaro (Tirzepatide) Is: Mechanism and Pharmacology
The active molecule in Mounjaro is tirzepatide. It is a synthetic 39-amino acid peptide developed by Eli Lilly, with molecular weight 4,813.5 Da and CAS number 2023788-19-2. Tirzepatide is designed as a “twincretin” — a single molecular entity with agonist activity at two distinct receptors: the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R). This distinguishes it from all previous compounds in the incretin agonist class, including semaglutide, which acts solely at the GLP-1 receptor.
The GIP receptor and GLP-1 receptor are both expressed in pancreatic beta cells, where they stimulate insulin secretion in a glucose-dependent manner — meaning only when blood glucose is elevated, reducing the risk of hypoglycaemia seen with insulin secretagogues. Both receptors are also expressed in the hypothalamus, adipose tissue, the gut, and the cardiovascular system, providing multiple potential mechanisms through which tirzepatide exerts its metabolic effects beyond simple insulin stimulation.
GIP Receptor Agonism: The Novel Component
The GIP receptor component of tirzepatide’s mechanism was initially controversial in the field, because GIP signalling was understood to be impaired or counterproductive in type 2 diabetes — early research had even explored GIP receptor antagonism as a therapeutic strategy. The observation that GIP receptor agonism at tirzepatide’s GIP:GLP-1 activity ratio (approximately 5:1 at GIP:GLP-1) produced markedly superior metabolic outcomes to GLP-1 receptor agonism alone in clinical trials was a significant scientific finding. Understanding whether this reflects direct adipose effects of GIPR agonism, central nervous system satiety signalling, enhancement of GLP-1 receptor sensitivity, or a combination of mechanisms is an active area of research — and one reason researchers interested in incretin pharmacology study compounds like tirzepatide in laboratory settings.
Half-Life and Dosing Interval
Tirzepatide has a plasma half-life of approximately 5 days, enabled by a C20 fatty diacid modification (via a gamma-glutamic acid linker) that promotes albumin binding and protects the molecule from enzymatic degradation. This pharmacokinetic profile supports once-weekly subcutaneous dosing in clinical use. In laboratory research settings, the extended half-life and albumin-binding properties of the molecule are relevant to experimental design considerations for in vitro and in vivo studies.
The SURPASS Trial Programme: What Doses Were Studied
The SURPASS (Tirzepatide Once Weekly for the Treatment of Obesity) programme comprises five Phase III trials (SURPASS-1 through SURPASS-5) that established the evidence base for tirzepatide’s approval in type 2 diabetes management. Alongside SURPASS, the SURMOUNT programme (SURMOUNT-1 through SURMOUNT-4) evaluated tirzepatide at the same dose range for chronic weight management in participants with and without type 2 diabetes.
Across the entire SURPASS programme, tirzepatide was evaluated at three therapeutic doses: 5mg, 10mg, and 15mg once weekly. These are the Mounjaro dosage arms that appear in published clinical trial data. An initiation dose of 2.5mg once weekly for the first 4 weeks was used in SURPASS trials as a tolerability step — analogous to the 0.25mg initiation step in semaglutide’s SUSTAIN programme — and is not considered a therapeutic dose in the trial literature.
SURPASS-1: Tirzepatide vs. Placebo (Monotherapy)
SURPASS-1 evaluated tirzepatide as monotherapy (without background antidiabetic medication) against placebo over 40 weeks in 478 adults with type 2 diabetes inadequately controlled with diet and exercise alone. Published outcomes demonstrated dose-dependent HbA1c reductions: −1.87% (5mg), −1.89% (10mg), and −2.07% (15mg) versus −0.04% for placebo. Body weight reductions were −7.0 kg (5mg), −7.8 kg (10mg), and −9.5 kg (15mg). Critically, HbA1c below the 7.0% threshold was achieved by 87%–92% of tirzepatide-treated participants at 40 weeks, compared with 20% for placebo.
SURPASS-2: Head-to-Head vs. Semaglutide 1mg
SURPASS-2 is the landmark head-to-head trial that positioned tirzepatide directly against semaglutide 1mg — the highest approved clinical dose of semaglutide at the time of trial design. Conducted in 1,879 adults with type 2 diabetes on metformin background therapy over 40 weeks, it is the most cited direct comparison in the incretin agonist class.
Published results in the New England Journal of Medicine (Frias et al. 2021) showed: at the Mounjaro 5mg dose, mean HbA1c reduction of −2.01% vs. −2.07% for semaglutide 1mg (non-inferior); at 10mg, −2.24% vs. −2.07% (superior); at 15mg, −2.46% vs. −2.07% (superior, with a statistically significant adjusted mean difference of −0.39%). Body weight changes followed a similar pattern: −5.5 kg (tirzepatide 5mg), −7.8 kg (10mg), −8.8 kg (15mg), compared with −5.7 kg for semaglutide 1mg. The 15mg tirzepatide arm produced the largest head-to-head glycaemic and weight difference versus an active comparator recorded in a GLP-1 class trial at that time.
SURPASS-3 through SURPASS-5: Additional Comparator Contexts
SURPASS-3 compared tirzepatide against insulin degludec (a long-acting basal insulin) in participants on metformin ± SGLT-2 inhibitor, demonstrating superior HbA1c reduction and significant body weight reduction versus weight gain in the insulin arm. SURPASS-4 evaluated tirzepatide versus insulin glargine in a high-cardiovascular-risk population, with 52 weeks of follow-up, confirming superiority of tirzepatide on glycaemic endpoints with a favourable body weight profile. SURPASS-5 studied tirzepatide added to insulin glargine background therapy. Across all five SURPASS trials, the dose-response pattern was consistent: the 15mg dose produced the largest effect on HbA1c and body weight, with the 5mg and 10mg doses showing intermediate, clinically meaningful effects.
SURPASS-CVOT: Cardiovascular Outcomes Programme
The SURPASS-CVOT programme enrolled more than 12,500 participants with type 2 diabetes at elevated cardiovascular risk across three dose arms (5mg, 10mg, 15mg). Cardiovascular outcomes research in the incretin class is significant because semaglutide’s SUSTAIN-6 trial established a cardiovascular protective signal for GLP-1 receptor agonism; understanding whether tirzepatide’s GIP receptor component modifies this cardiovascular effect (positively or negatively) is a question of substantial clinical and scientific interest. Published cardiovascular outcomes data from SURPASS-CVOT are expected in 2025–2026 and will be a landmark in incretin pharmacology research.
The SURMOUNT Programme: Tirzepatide Dosage in Obesity Research
The SURMOUNT programme moved the dose-response research into obesity populations — participants with BMI ≥27 kg/m² (with at least one weight-related comorbidity) or BMI ≥30 kg/m², without type 2 diabetes. This distinction matters for researchers: in the absence of diabetes, the glucose-lowering effect of tirzepatide is less prominent, while the body weight and metabolic effects on adipose tissue, hepatic lipid content, and insulin sensitivity are studied in isolation from the diabetes context.
SURMOUNT-1 (Jastreboff et al. 2022, New England Journal of Medicine) — the pivotal obesity trial — enrolled 2,539 adults without type 2 diabetes over 72 weeks at tirzepatide 5mg, 10mg, and 15mg once weekly versus placebo. Mean body weight reductions were −15.0% (5mg), −19.5% (10mg), and −20.9% (15mg) versus −3.1% for placebo. At the 15mg dose, 63% of participants achieved ≥20% body weight reduction — a threshold that had not been demonstrated by any previously approved pharmacotherapy for obesity. The mean absolute weight reduction at 15mg was approximately 22.5 kg over 72 weeks in this population.
| Trial / Dose | Primary Endpoint | Key Outcome | Duration |
|---|---|---|---|
| SURPASS-1 / 5mg | HbA1c reduction | −1.87% HbA1c; −7.0 kg body weight | 40 weeks |
| SURPASS-1 / 10mg | HbA1c reduction | −1.89% HbA1c; −7.8 kg body weight | 40 weeks |
| SURPASS-1 / 15mg | HbA1c reduction | −2.07% HbA1c; −9.5 kg body weight | 40 weeks |
| SURPASS-2 / 15mg vs. Semaglutide 1mg | HbA1c reduction (superiority) | −2.46% vs. −2.07% (adjusted diff: −0.39%) | 40 weeks |
| SURMOUNT-1 / 5mg (obesity) | % body weight change | −15.0% body weight vs. −3.1% placebo | 72 weeks |
| SURMOUNT-1 / 10mg (obesity) | % body weight change | −19.5% body weight vs. −3.1% placebo | 72 weeks |
| SURMOUNT-1 / 15mg (obesity) | % body weight change | −20.9% (~22.5 kg); 63% achieved ≥20% reduction | 72 weeks |
Source: Rosenstock et al. (2021) SURPASS-1, NEJM; Frias et al. (2021) SURPASS-2, NEJM; Jastreboff et al. (2022) SURMOUNT-1, NEJM. Mean trial population data under clinical supervision. Not predictions of individual outcomes.
The SURPASS-2 trial was significant not simply for the numbers it produced, but for the scientific question it definitively answered: does adding GIP receptor agonism to GLP-1 receptor agonism produce meaningfully superior metabolic outcomes? Before tirzepatide, the field had debated whether GIP receptor agonism in the context of type 2 diabetes was even beneficial — GIP signalling was known to be blunted in insulin-resistant states, and some researchers had proposed GIPR antagonism as a therapeutic direction. SURPASS-2’s outcomes settled that question in clinical populations: the dual agonist outperformed the best-in-class GLP-1-only agent at the highest approved dose, by a clinically and statistically meaningful margin. Understanding the molecular pharmacology underpinning that difference — whether at the receptor level, the signalling cascade level, or the tissue-level crosstalk between GIPR and GLP-1R pathways — is precisely the kind of question that drives laboratory research into compounds like research-grade tirzepatide.
Dual GIP/GLP-1 Research: Tirzepatide Available Now
Tirzepatide 10mg — HPLC ≥99% purity. Batch COA. Also available: Semaglutide 10mg (GLP-1 only comparator) and Retatrutide 10mg (triple agonist).
Prescription-only medicine in many jurisdictions. For research purposes only. Not for human consumption.
Safety Signals Documented in SURPASS Trials
The published SURPASS safety data is relevant for researchers building preclinical or translational models. Across all five SURPASS trials, the most frequently documented adverse events were gastrointestinal: nausea (dose-dependent, highest at 15mg), diarrhoea, and vomiting — predominantly during dose escalation phases and typically transient. These GI effects are mechanistically expected with GLP-1 receptor agonism (gastric emptying delay, central vagal signalling) and were not unique to the GIP receptor component.
Hypoglycaemia rates in the SURPASS trials were low when tirzepatide was used without insulin or sulphonylurea background therapy — consistent with the glucose-dependent mechanism of both GIP receptor and GLP-1 receptor-mediated insulin secretion. In SURPASS-3 and SURPASS-4, where tirzepatide was combined with insulin, insulin dose reduction protocols were incorporated into the trial design to mitigate hypoglycaemia risk.
No cardiovascular safety signal has emerged from completed SURPASS trials to date. Gallbladder-related events (cholelithiasis) were observed at a low but elevated rate versus comparators in SURMOUNT-1, consistent with a class effect observed across rapid weight-reducing therapies. These are research-relevant observations for the in vitro and in vivo study of metabolic compounds — they are not prescribing guidance.
Tirzepatide vs. Semaglutide: What the Research Differences Mean
For researchers working with metabolic peptides, the mechanistic distinction between tirzepatide and semaglutide is the most scientifically interesting aspect of the published clinical literature. Semaglutide acts exclusively at the GLP-1 receptor — a well-characterised mechanism with the full SUSTAIN trial programme and extensive post-marketing pharmacovigilance data. Tirzepatide adds simultaneous GIP receptor agonism at a ratio that, at the concentrations achieved clinically, produces additive or supra-additive metabolic effects compared with GLP-1 receptor agonism alone.
The implications for laboratory research include: studies comparing GLP-1R-only versus dual GIPR/GLP-1R agonism in islet biology, adipocyte differentiation and lipolysis assays, hepatic glucose output models, or hypothalamic appetite circuit research can use semaglutide and tirzepatide as tools to dissect which aspects of the observed phenotype are attributable to each receptor pathway. Pure Grade Labs makes both compounds available for exactly this kind of comparative research.
Beyond Tirzepatide: Retatrutide and the Triple Agonist Frontier
The research trajectory from GLP-1 agonism (semaglutide) to dual GIP/GLP-1 agonism (tirzepatide) points toward triple agonism as the next chapter in this pharmacological class. Retatrutide — also from Eli Lilly — adds glucagon receptor agonism to the GIP/GLP-1 receptor profile, creating a triple incretin agonist currently in Phase III clinical trials. The glucagon receptor component introduces direct thermogenic and hepatic effects not present in tirzepatide, with early Phase II data suggesting body weight reductions potentially exceeding those of tirzepatide at the doses studied.
For metabolic researchers, this progression — from single to dual to triple agonism — provides a hierarchy of tools for dissecting receptor-specific contributions to metabolic regulation. Pure Grade Labs supplies research-grade retatrutide 10mg alongside tirzepatide and semaglutide for this purpose. All three are Prescription Only Medicines in clinical contexts; all three are available from Pure Grade Labs for laboratory research only, not for human consumption.
Frequently Asked Questions
Can you tell me what Mounjaro dosage to start on?
No. Pure Grade Labs is a research chemical supplier, not a prescribing service. Mounjaro dosage decisions require assessment by a licensed medical prescriber who evaluates your individual health history, current medications, contraindications, and clinical suitability. The published Mounjaro Summary of Product Characteristics (SmPC) — available from the MHRA and Eli Lilly — describes the approved initiation and escalation schedule, but applying that to any individual requires clinical oversight. Please speak to your GP, endocrinologist, or a licensed private prescriber.
What Mounjaro dosage levels were tested in clinical trials?
The SURPASS and SURMOUNT clinical programmes evaluated tirzepatide at three therapeutic doses: 5mg, 10mg, and 15mg once weekly. A 2.5mg once-weekly initiation dose was used for the first four weeks in trial protocols to allow gastrointestinal tolerability adaptation — it is not a therapeutic dose in the published literature. The 5mg, 10mg, and 15mg doses are what “Mounjaro dosage” refers to in the published clinical evidence base, and all three produced statistically significant and clinically meaningful improvements in HbA1c and body weight versus comparators.
How does Mounjaro differ from Ozempic at the mechanism level?
Ozempic (semaglutide) is a GLP-1 receptor agonist only — it acts at one receptor. Mounjaro (tirzepatide) is a dual agonist: it activates both the GIP receptor and the GLP-1 receptor simultaneously. In clinical trials (SURPASS-2), tirzepatide at 15mg outperformed semaglutide 1mg on both HbA1c reduction and body weight reduction — a finding attributed in the research literature to the additive metabolic effects of co-activating both incretin receptors. This mechanistic difference is the reason tirzepatide is classified as a novel pharmacological class (dual GIP/GLP-1 receptor agonist) rather than simply a more potent GLP-1 agonist.
What does Pure Grade Labs sell and what is it for?
Pure Grade Labs sells research-grade tirzepatide 10mg as a lyophilised powder for laboratory research purposes only — not for human consumption, self-administration, or any therapeutic application. It is not Mounjaro. It is not a pharmaceutical product. It cannot legally be used as a substitute for a prescribed medicine. If you need tirzepatide as a patient, you need a prescription from a licensed prescriber.
What were the key safety findings in the SURPASS trials?
Across the SURPASS programme, the most commonly documented adverse events were gastrointestinal — nausea (dose-dependent, highest at 15mg), diarrhoea, and vomiting — predominantly during dose escalation phases and typically resolving over time. Hypoglycaemia rates were low in arms without insulin or sulphonylurea background. Gallbladder-related events were observed at a low but elevated rate in SURMOUNT-1, consistent with class effects in rapid weight-reduction contexts. These are published trial population safety observations — they are not a safety profile for any individual and should not be treated as such outside a clinical context.
Is there a higher-potency compound being researched beyond tirzepatide?
Yes. Retatrutide is a triple GIP/GLP-1/glucagon receptor agonist from Eli Lilly currently in Phase III clinical trials. Early Phase II data (Jastreboff et al. 2023, NEJM) showed mean body weight reductions of up to 24.2% over 48 weeks at the highest studied dose in adults with obesity — suggesting a further step-up in metabolic potency. Retatrutide is of significant research interest to metabolic pharmacologists studying the contribution of glucagon receptor agonism to the dual incretin agonist mechanism.
The Complete Incretin Research Toolkit
Semaglutide (GLP-1), Tirzepatide (GIP/GLP-1), and Retatrutide (GIP/GLP-1/GCG) — all HPLC ≥99%. UK supply. For laboratory research only.
Prescription-only medicines in many jurisdictions. Not for human consumption.
Summary
Mounjaro dosage decisions are clinical decisions — they belong to licensed prescribers, not to information articles, research chemical suppliers, or any source that has not assessed your individual medical situation. This article has explained what the SURPASS and SURMOUNT clinical trial programmes actually studied: tirzepatide evaluated at therapeutic doses of 5mg, 10mg, and 15mg once weekly, with consistent dose-dependent improvements in HbA1c and body weight across all trial contexts, culminating in the landmark SURMOUNT-1 finding of 20.9% mean body weight reduction at 15mg over 72 weeks — the highest efficacy published for any approved incretin-class pharmacotherapy.
The science underpinning these outcomes — dual GIP receptor and GLP-1 receptor agonism, the structural pharmacology of tirzepatide’s C20-modified 39-amino acid scaffold, the receptor crosstalk mechanisms that may explain the supra-additive efficacy versus GLP-1-only agents — represents an active and rapidly evolving area of metabolic pharmacology research. Pure Grade Labs supplies research-grade tirzepatide 10mg for researchers studying these mechanisms in vitro. For comparative receptor pharmacology, research-grade semaglutide 10mg (GLP-1 receptor agonist only) and research-grade retatrutide 10mg (triple GIP/GLP-1/glucagon agonist) are also available.
If you are a patient who needs access to Mounjaro, the correct route is a licensed prescriber — GP, endocrinologist, or a regulated private prescribing service. All three compounds discussed in this article are Prescription Only Medicines in clinical contexts, and sourcing them outside the licensed prescribing pathway carries significant risks to health and to legal compliance. Pure Grade Labs does not sell Mounjaro and does not provide prescribing services.
References
- Rosenstock J et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 44(6):1433-1443. DOI: 10.2337/dc21-0185
- Frias JP et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). New England Journal of Medicine. 385:503-515. DOI: 10.1056/NEJMoa2107519
- Ludvik B et al. (2021). Tirzepatide versus insulin degludec once daily in patients with type 2 diabetes (SURPASS-3). Lancet. 398(10300):583-598. DOI: 10.1016/S0140-6736(21)01443-4
- Del Prato S et al. (2021). Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). Lancet. 398(10313):1811-1824. DOI: 10.1016/S0140-6736(21)02188-7
- Jastreboff AM et al. (2022). Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 387:205-216. DOI: 10.1056/NEJMoa2206038
- Jastreboff AM et al. (2023). Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. New England Journal of Medicine. 389:514-526. DOI: 10.1056/NEJMoa2301972
- Eli Lilly and Company. (2023). Mounjaro (tirzepatide) UK Summary of Product Characteristics. MHRA. medicines.org.uk
- Human Medicines Regulations 2012. SI 2012/1916. UK Statutory Instruments. legislation.gov.uk